Jim W. Larrick

Theron Pharmaceuticals, Inc. provides treatments for COPD and asthma. It is a biotechnology company, develops long acting M3 muscarinic antagonist (LAMA) products for the treatment of chronic respiratory diseases. The firm’s product TRN-157, a preclinical development therapy focuses on treating chronic obstructive pulmonary disease and severe asthma. The company was founded by M. Venkatraman, Xiaoming Zhang and Jurg Pfister in 2008 and is headquartered in Sunnyvale, CA.

ChinaBio LLC operates as an investment, consulting and media company which helps life science companies. It organizes life science investment and partnering conferences in China. The firm’s conferences comprise investor forums, partnering forums, executive workshops and SEED business plan competitions. It also offers consulting services, including China strategy development, market and competitive intelligence, technology survey and search, partnering arrangement, CRO and CMO selection, management, business strategy, funding strategy, assistance, collaboration agreements, in-licensing, out-licensing, the United States operations consulting services, investment analysis, due diligence and portfolio analysis. The company serves executives, entrepreneurs, investors, pharma and multinational companies. ChinaBio was founded in April 2007 by Greg B. Scott and James W. Larrick and is headquartered in Shanghai, China.

Presidio Partners is a venture capital firm founded in the year 1989 by Thomas R. Baruch. The firm is headquartered in San Francisco, California.

Velocity Pharmaceutical Development LLC develops pharmaceutical drugs. It identifies drug candidates, target markets and designing and managing outsourced clinical trials. The firm seeks to acquire promising drug candidates, generally within a year of their entering human clinical trials or after initial human clinical data have been generated. The company was founded by David Collier, Ed Schnipper, Jim Larrick and Andy Perlman in 2011 and is headquartered in South San Francisco, CA.

Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA.

Eumentis Therapeutics, Inc. manufactures novel drugs. The American company was founded by Mark A. Tepper and he has been the CEO since incorporation.

Velocity Pharmaceutical Holdings LLC operates as a holding American company.